A hi-tech boom helps the medicine go down

Injections without needles, pills with microchips - drug delivery systems are a rapidly growing secto

Faced with the prospect of having a needle jabbed into their private parts, most men would politely decline, but until recently such an injection has been the most effective way to cure male impotence.

Then Vivus, a US drug delivery company, found an alternative - packaging the same drug into pellets to be delicately inserted into the urethra - and took half the $60m world market in four months.

The next improvement could come from PowderJect, which will float on the London stock market this month and has a pain-free, needle-less injection. "If all men suffering from impotence had treatment, this would be a $500m market," says Paul Drayson, PowderJect's chairman.

As this example shows starkly, the way a drug is given can matter at least as much as what it does. This is the premise behind the drug delivery industry. The sector has come from nowhere 10 years ago, to capture a $12bn slice of the $150bn world-wide pharmaceutical market. Moreover drug delivery is growing fast - at 15-20 per cent a year, twice as fast as the wider drugs market.

The product that put drug delivery on the map was a heart pill called Procardia XL. The first version of Procardia, sold by Pfizer, had to be swallowed three times a day, restricting sales to $400m a year, and in 1989 was about to lose its patent.

In a well-timed move, Pfizer linked up with Alza - a then tiny drug delivery company - which came up with a once-a-day version, reviving Procardia's patent and tripling sales to $1.2bn. Felix Theeuwes, Alza's president of research and development, remembers the excitement: "We enormously expanded the market for angina drugs. Our technology gave Pfizer its first billion-dollar drug."

The range of delivery technologies today is vast and ingenious. It includes everything from simple skin patches, inhalers, gels and nasal sprays to implants, pills with microchips and contact lenses that release drugs into the eye.

SkyePharma's Geomatrix technology, for example, can release a drug in tablet form immediately, slowly over days or in prescribed bursts so that, say, someone at risk of heart attack could take a pill before bed and get regular doses throughout the night. Elan is developing a smart pill embedded with a microchip and Alza has a titanium implant, no bigger than a matchstick, that leaks out a cancer drug over a year.

The most exciting area in delivery, though, is driven by the biotechnology industry, which is developing protein and peptide-based compounds like insulin. These large and complex molecules have to be given by injection because they are digested if swallowed and are too big to pass normally through the skin.

Among the many companies working in this area, Cortecs is developing insulin and brittle bone pills, Inhale has an insulin dry powder inhaler and PowderJect a helium pump which can drive molecules through the skin at three times the speed of sound.

For both patients and healthcare payers, there are huge benefits in all this - the easier a drug is to take, the more compliant a patient will be. Alex Zisson of US broker Hambrecht & Quist says the cost benefits of improving compliance are central to the delivery sector: "In the US, 28 per cent of hospital admissions can be traced to people not taking their drugs properly."

Glen Travers, chairman of Cortecs, says that less than a third of women prescribed hormone patches for brittle bones stay on the treatment after two years: "The cost to the US government in hospital fees to treat broken bones is $10bn a year and growing."

For the big pharmaceutical companies, meanwhile, a clever delivery system can extend the patent life of their drugs, generating substantial extra revenues. The number of alliances with specialist delivery companies is growing.

Alza's Mr Theeuwes says: "It is financially unrewarding for pharma groups to spend millions on their own technologies to improve just one drug." Donal Geaney, president of Elan, says: "Many medicines stay on the shelf because they cannot be delivered properly and this is costly."

Rolf Stahel, chief executive of Shire, sees another reason for alliances: "Research directors in big pharma groups are not enthusiastic about delivery. It does not lead to Nobel prizewinners."

Investors, though, should be more excited. While the small numbers of UK delivery companies are normally lumped in with their biotechnology cousins, as Jo Walton of broker Lehman Brothers points out, their risk profiles are substantially different.

"Delivery companies work on existing chemicals, where all the data - animal tests, safety, which patients to target, which clinical trials to use - are already known. Times to market are shorter and the chances of success are higher." Mr Zisson agrees: "It takes a delivery company about three to four years to get a drug to market, compared to six years for a normal drug."

Financial risks are also lower. Robert Chess, chief executive of Inhale, estimates his research costs are a tenth those of an average biotech company and with three times as many products, risks are spread.

And as Richard Stewart, SkyePharma's finance director, points out, the development costs of reformulating an old drug are borne by clients, while established sales and marketing teams can push the new version at minimal cost: "All this means more in royalties," he says.

Though royalties can limit upside, companies working in protein delivery or on big drugs stand to gain substantial returns and make profits sooner than most biotechs. So far, their potential is more apparent in the US. According to Ms Walton: "Investors are more cynical in the UK, where hopefuls like Cortecs have not yet made it. In the US there are some huge and profitable companies." UK delivery companies may not be far behind.

Drug delivery contenders

Company Market value

Alza Corp (US) $2.5bn

Cortecs (UK) pounds 277m

Cygnus $292m

Dura Pharmacls (US) $1.7bn

Elan Corp (Irish/US) pounds 2.5bn

Ethical Holdings (US/UK) $78m

Guilford Pharmacls $501m

Inhale (US) $307m

Liposome Company (US) $993m

PowderJect (UK) pounds 109m

RP Scherer $1.3bn

Shire Pharmacls (UK) pounds 198m

SkyePharma (UK) pounds 307m

TheraTech (US) $237m

Vivus (US) $13m

scienceExcitement from alien hunters at 'evidence' of extraterrestrial life
Life and Style
Customers can get their caffeine fix on the move
food + drink
newsRyan Crighton goes in search of the capo dei capi

Arts and Entertainment
Actors front row from left, Jared Leto, Jennifer Lawrence, Meryl Streep, Ellen DeGeneres, Bradley Cooper, Peter Nyongío Jr., and, second row, from left, Channing Tatum, Julia Roberts, Kevin Spacey, Brad Pitt, Lupita Nyongío and Angelina Jolie as they pose for a
Life and Style
techCould new invention save millions in healthcare bills?
David Moyes gets soaked
sport Moyes becomes latest manager to take part in the ALS challenge
A meteor streaks across the sky during the Perseid Meteor Shower at a wind farm near Bogdanci, south of Skopje, Macedonia, in the early hours of 13 August
voicesHagel and Dempsey were pure Hollywood. They only needed Tom Cruise, says Robert Fisk
peopleEnglishman managed quintessential Hollywood restaurant Chasen's
Life and Style
food + drinkHarrods launches gourmet food qualification for staff
Arts and Entertainment
Michael Flatley prepares to bid farewell to the West End stage
danceMichael Flatley hits West End for last time alongside Team GB World champion Alice Upcott
ebooksAn evocation of the conflict through the eyes of those who lived through it
Life and Style
Horst P Horst mid-fashion shoot in New York, 1949
fashionFar-reaching retrospective to celebrate Horst P Horst's six decades of creativity
Members and supporters of the lesbian, gay, bisexual, transgender (LGBT) community walk with a rainbow flag during a rally in July
Life and Style
Black Ivory Coffee is made using beans plucked from elephants' waste after ingested by the animals
food + drinkFirm says it has created the "rarest" coffee in the world
Life and Style

As Voltaire once said, “Ice cream is exquisite. What a pity it isn’t illegal”

Life and Style
food + drinkThese simple recipes will have you refreshed within minutes
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Service Desk Analyst- Desktop Support, Helpdesk, ITIL

£20000 - £27000 per annum: Harrington Starr: Service Desk Analyst- (Desktop Su...

Service Desk Analyst - (Active Directory, Support, London)

£25000 - £35000 per annum: Harrington Starr: Service Desk Analyst - (Active Di...

Junior Quant Analyst - C++, Boost, Data Mining

£30000 - £50000 per annum: Harrington Starr: Junior Quant Analyst - C++, Boost...

Junior Quant Analyst (Machine Learning, SQL, VBA)

£30000 - £50000 per annum: Harrington Starr: Junior Quant Analyst (Machine Lea...

Day In a Page

All this talk of an ‘apocalyptic’ threat is simply childish

Robert Fisk: All this talk of an ‘apocalyptic’ threat is simply childish

Chuck Hagel and Martin Dempsey were pure Hollywood. They only needed Tom Cruise
Mafia Dons: is the Camorra in control of the Granite City?

Mafia Dons: is the Camorra in control of the Granite City?

So claims an EU report which points to the Italian Mob’s alleged grip on everything from public works to property
Emmys look set to overhaul the Oscars as Hollywood’s prize draw

Emmys look set to overhaul the Oscars as Hollywood’s prize draw

Once the poor relation, the awards show now has the top stars and boasts the best drama
What happens to African migrants once they land in Italy during the summer?

What happens to migrants once they land in Italy?

Memphis Barker follows their trail through southern Europe
French connection: After 1,300 years, there’s a bridge to Mont Saint-Michel

French connection: After 1,300 years, there’s a bridge to Mont Saint-Michel

The ugly causeway is being dismantled, an elegant connection erected in its place. So everyone’s happy, right?
Frank Mugisha: Uganda's most outspoken gay rights activist on changing people's attitudes, coming out, and the threat of being attacked

Frank Mugisha: 'Coming out was a gradual process '

Uganda's most outspoken gay rights activist on changing people's attitudes, coming out, and the threat of being attacked
Radio 1 to hire 'YouTube-famous' vloggers to broadcast online

Radio 1’s new top ten

The ‘vloggers’ signed up to find twentysomething audience
David Abraham: Big ideas for the small screen

David Abraham: Big ideas for the small screen

A blistering attack on US influence on British television has lifted the savvy head of Channel 4 out of the shadows
Florence Knight's perfect picnic: Make the most of summer's last Bank Holiday weekend

Florence Knight's perfect picnic

Polpetto's head chef shares her favourite recipes from Iced Earl Grey tea to baked peaches, mascarpone & brown sugar meringues...
Horst P Horst: The fashion photography genius who inspired Madonna comes to the V&A

Horst P Horst comes to the V&A

The London's museum has delved into its archives to stage a far-reaching retrospective celebrating the photographer's six decades of creativity
Mark Hix recipes: Try our chef's summery soups for a real seasonal refresher

Mark Hix's summery soups

Soup isn’t just about comforting broths and steaming hot bowls...
Tim Sherwood column: 'It started as a three-horse race but turned into the Grand National'

Tim Sherwood column

I would have taken the Crystal Palace job if I’d been offered it soon after my interview... but the whole process dragged on so I had to pull out
Eden Hazard: Young, gifted... not yet perfect

Eden Hazard: Young, gifted... not yet perfect

Eden Hazard admits he is still below the level of Ronaldo and Messi but, after a breakthrough season, is ready to thrill Chelsea’s fans
Tim Howard: I’m an old dog. I don’t get too excited

Tim Howard: I’m an old dog. I don’t get too excited

The Everton and US goalkeeper was such a star at the World Cup that the President phoned to congratulate him... not that he knows what the fuss is all about
Match of the Day at 50: Show reminds us that even the most revered BBC institution may have a finite lifespan – thanks to the opposition

Tom Peck on Match of the Day at 50

The show reminds us that even the most revered BBC institution may have a finite lifespan – thanks to the opposition